This XML file does not appear to have any style information associated with it. The document tree is shown below. <!-- Generated on Thu, 25 Nov 2021 15:50:19 -0500 --> <rss xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"> <channel> <title>ADMA Biologics, Inc. (ADMA) News</title> <link>https:///rss</link> <description>The latest news released by ADMA Biologics, Inc. (ADMA)</description> <language>en-us</language> <generator>Equisolve Investor Relations Suite</generator> <item> <title>ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors</title> <link>https://www.admabiologics.com/investors/press-releases/detail/523/adma-biologics-senior-vice-president-of-plasma-services</link> <pubDate>Wed, 17 Nov 2021 07:00:00 -0500</pubDate> <guid isPermaLink="true">https://www.admabiologics.com/investors/press-releases/detail/523/adma-biologics-senior-vice-president-of-plasma-services</guid> <content:encoded> <![CDATA[ <p align="left">RAMSEY, N.J. and BOCA RATON, Fla., Nov. 17, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Cyndi Tolman, ADMA’s Senior Vice President of Plasma Services, has been elected to serve on the PPTA Source Board of Directors (“PPTA Source Board”) for the 2022 to 2024 election term. <br></p> <p>“Mrs. Tolman’s appointment to the PPTA Source Board of Directors is a well-deserved testament to her leadership capabilities and accomplishments as a part of the rapid and successful expansion of the ADMA BioCenters collection network,” said Adam Grossman, President and Chief Executive Officer of ADMA. “ADMA welcomes the opportunity to have a voice on the PPTA Source Board and we are confident in Cyndi’s ability and decades-long experience, that will allow her to provide valuable input to further the industry’s mission to advocate for access of plasma-derived therapies for patients in need.”</p> <p>“I am honored to have been elected by my peers to this esteemed board and look forward to bringing ideas and recommendations based upon my over 20 years of plasma collections experience to the PPTA,” said Cynthia Tolman, Senior Vice President, Plasma Services of ADMA BioCenters. “Our recent expansion of ADMA’s collection center network, including the implementation of the latest technology in collection methods, coupled with our regulatory and quality experience, will allow for additional insights into ways we can enhance the donor experience and ensure the safety of our valuable and generous plasma donors who give the gift of saving lives with every donation they make.”</p> <p>The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by small patient populations worldwide to treat a variety of rare diseases and serious medical conditions. PPTA works globally to advocate for access to and affordability of therapies for patients, engage in constructive dialogue with regulatory agencies, and collaborate with patient advocacy organizations. Mrs. Tolman is one of five new appointments to the PPTA Source Board, which consists of global representatives from the plasma industry as to ensure balanced representation.</p> <p align="justify"><strong>About ADMA BioCenters</strong></p> <p align="justify">ADMA BioCenters operates U.S. Food and Drug Administration (FDA)-licensed facilities specializing in the collection of human plasma used to make special medications for the treatment and prevention of certain infectious diseases. Managed by a team of experts who have decades of experience in the specialized field of plasma collection, ADMA BioCenters provides a safe, professional and pleasant donation environment. ADMA BioCenters strictly follows FDA regulations and guidance and enforces current good manufacturing practices (cGMP) in all of its facilities. For more information about ADMA BioCenters, please visit <a href="https://www.globenewswire.com/Tracker?data=cBjljO_g91UuJJO4qYvdI4kjkcu1nbSP00ye6acYKl5xrwFncMujq5QNgADzz0OX6raUwHVpT36HvTdwIfuKuYPJi_gYTs6iwbqdU_M9kSo=" rel="nofollow" target="_blank">www.admabiocenters.com</a>.</p> <p align="justify"><strong>About ADMA Biologics, Inc. (ADMA) </strong></p> <p align="justify">ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three FDA-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-licensed source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=cBjljO_g91UuJJO4qYvdI3CHhnUyA_4dd3RD9RGs2aXqeR1uBhjFbLeUj0055zxlTxdzGHBvRXogJOSaSNY9HbwF36TeafF9jhPfqBXM-kI=" rel="nofollow" target="_blank">www.admabiologics.com</a>.</p> <p align="justify"><strong>COMPANY</strong> <strong>CONTACT</strong><strong>: </strong><br>Skyler Bloom<br>Director, Investor Relations and Corporate Strategy | 201-478-5552 | <a href="https://www.globenewswire.com/Tracker?data=CaiL5zUAjSobrnUh2vkyoEIKb-lkoDUwIqkwO6KAPzfcq6KrLa7PjjGe1thyEsn9oHrgqUENdRL2FISLSQl_VvaKJ43YDcCSlHm0gdbPjIs=" rel="nofollow" target="_blank">sbloom@admabio.com</a></p> <p><strong>INVESTOR RELATIONS CONTACT:</strong><br>Michelle Pappanastos <br>Senior Managing Director, Argot Partners | 212-600-1902 | <a href="https://www.globenewswire.com/Tracker?data=v9WThd-punlx_evzxTzi2i4kBBm4SJ5JOzomZ0E1DClg2OqfcEtIIAN_f-dOn6oRNZkU-yRfIVRJA4kRZ9wMc8YqJ7CIaA8dMgLmhLwcm5Y=" rel="nofollow" target="_blank">michelle@argotpartners.com</a></p> <p> </p> <img class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=ODM5NTY3NCM0NTU3ODI1IzIwMjM3MzA="> <br><img src="https://ml.globenewswire.com/media/Nzg5MDEyOTUtYTI1NC00NDViLTkwNzAtNjcxNzE4ZWJiNTMxLTEwMzUyOTc=/tiny/ADMA-Biologics-Inc-.png"><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/468b61b4-73b9-495e-a4be-f4823782b2fd"><img src="https://ml.globenewswire.com/media/468b61b4-73b9-495e-a4be-f4823782b2fd/small/adma-biologics-rgb-l-092115p-jpg.jpg" border="0" width="150" height="52" alt="Primary Logo"></a></p> Source: ADMA Biologics, Inc. ]]> </content:encoded> </item> <item> <title>ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC</title> <link>https://www.admabiologics.com/investors/press-releases/detail/522/adma-biologics-advances-plasma-collection-center-expansion</link> <pubDate>Tue, 16 Nov 2021 07:00:00 -0500</pubDate> <guid isPermaLink="true">https://www.admabiologics.com/investors/press-releases/detail/522/adma-biologics-advances-plasma-collection-center-expansion</guid> <content:encoded> <![CDATA[ <h3 class="spr-ir-news-article-title">ADMA Now Collects Plasma from Six Vertically Integrated Centers with Three Additional Facilities Under Construction</h3> <p align="left">RAMSEY, N.J. and BOCA RATON, Fla. and MYRTLE BEACH, S.C., Nov. 16, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commencement of operations and initiation of donor plasma collections at its newest ADMA BioCenters location in Myrtle Beach, South Carolina. <br></p> <p>“ADMA continues to successfully advance its ADMA BioCenters expansion strategy, and in doing so, we believe is well-positioned to ensure continuity of plasma supply to support the significant revenue growth targets for the Company’s commercial Immune Globulin (IG) portfolio,” said Adam Grossman, President and Chief Executive Officer of ADMA. “With the opening of this Myrtle Beach plasma collection center, ADMA currently collects plasma from six centers and three additional centers are under construction. The Company remains on track to have 10 or more plasma collection centers licensed by the United States Food and Drug Administration (“FDA”) by year-end 2023, which we believe will support source plasma supply self-sufficiency as well as sustained quarter-over-quarter revenue growth,” concluded Mr. Grossman.</p> <p>ADMA BioCenters’ newest, state-of-the-art plasma collection center located in Myrtle Beach, South Carolina features automated registration, Haemonetics’ Persona® plasma collection solution for the NexSys PCS® system designed to shorten the donation process and increase collection yields, free Wi-Fi wireless network in the donor collection area, individual flat-screen TVs with cable at each donor station, and highly trained and certified staff who put donor comfort and safety first. At full capacity, the center expects to maintain a staff of up to 50 highly trained healthcare workers. Pursuant to updated FDA direction to obtain approval for plasma collection centers, sponsors are now required to collect plasma donations for three months prior to submitting a Biologics License Application (“BLA”) filing. Accordingly, ADMA expects to file its BLA for the Myrtle Beach, South Carolina plasma collection facility in approximately three months and anticipates a standard 12-month BLA review period by the FDA. In the meantime, ADMA is permitted to collect plasma donations at this site and, once the site is FDA approved, ADMA can utilize the plasma collected for further use in the manufacturing of life saving therapies.</p> <p>To learn more about the ADMA BioCenters donation process, and to schedule an appointment, please visit: <a href="https://www.globenewswire.com/Tracker?data=TWdaU0cCa1Yr72OnUHO8XpQeNk0XGaOjrneRRnlyjGxYCpqeQ1fHfVzD7iUmfby7QzD7SsZ6hwPhbuc8kXCf7cOhhkbr4evYTfZyD749jnw=" rel="nofollow" target="_blank">www.admabiocenters.com</a>, or visit in person at: 1100 A Legends Rd, Myrtle Beach, SC 29579.</p> <p align="justify"><strong>About ADMA BioCenters</strong></p> <p align="justify">ADMA BioCenters operates FDA-licensed facilities specializing in the collection of human plasma used to make special medications for the treatment and prevention of certain infectious diseases. Managed by a team of experts who have decades of experience in the specialized field of plasma collection, ADMA BioCenters provides a safe, professional and pleasant donation environment. ADMA BioCenters strictly follows FDA new regulations and guidance and enforces current good manufacturing practices (“cGMP”) in all of its facilities. For more information about ADMA BioCenters, please visit <a href="https://www.globenewswire.com/Tracker?data=TWdaU0cCa1Yr72OnUHO8XpQeNk0XGaOjrneRRnlyjGyN7sPMmKsZbFjq6hCuSJLkPPfF8eCT8kRgJ0b75gTWLgz_cJGdg9rXr2QBfrqJHdw=" rel="nofollow" target="_blank">www.admabiocenters.com</a>.</p> <p align="justify"><strong>About ADMA Biologics, Inc. (ADMA) </strong></p> <p align="justify">ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three FDA-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-licensed source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=TWdaU0cCa1Yr72OnUHO8XkRFmpjYFlLaCcDeeaZkWl2kfAFO3-WNz-a3Qf1k_bTGdJ5YTTt9unE24euBOX_B3FHMbZ94tV7M0onokbW06nw=" rel="nofollow" target="_blank">www.admabiologics.com</a>.</p> <p align="justify"><strong>About Haemonetics</strong></p> <p align="justify">Haemonetics (NYSE: “HAE”) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com. Persona®, a proprietary, patented solution built upon Haemonetics’ NexSys PCS® platform, tailors plasma collections to each donor’s individual characteristics and is clinically shown to yield +9% to 12% (based on baseline device, software configuration and donor population) more plasma per donation on average to maximize both cost-efficient output and patient impact from plasma collection centers. To learn more about Haemonetics, visit <a href="https://www.globenewswire.com/Tracker?data=RjR2LV6rq7wA21C9wp-_QWiPvqdD6jmPIdCStMJTAryZwSiPRPERTAiJh-8Me2eDio7wGJNidoRMMrcX98FyYcT44wDw8onuBLzkJbe2wYk=" rel="nofollow" target="_blank">www.haemonetics.com</a>.</p> <p align="justify"><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p> <p align="justify">This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 about ADMA Biologics, Inc. and its subsidiaries (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “anticipate,” “intend,” “target,” “plan,” “expect,” “believe,” “will,” “is likely,” “will likely,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements also include, but are not limited to, statements about ADMA’s future results of operations; plasma supply self-sufficiency; the strategic value of our ADMA Biocenters; yield enhancement resulting from the Persona® technology implementation; expansion plans and the goal of opening ten or more plasma collection centers approved by year-end 2023; timing relating to the filing, and review period, of a Biologics License Application for the Myrtle Beach, South Carolina facility and the number of employees at such location; and the use of plasma collected at the Myrtle Beach, South Carolina facility for production of immunoglobulin products. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.</p> <p align="justify"><strong>COMPANY</strong> <strong>CONTACT</strong><strong>: </strong><br>Skyler Bloom<br>Director, Investor Relations and Corporate Strategy | 201-478-5552 | <a href="https://www.globenewswire.com/Tracker?data=jTMOfHMEHi7zFQHNC6dJOwU87ajWY4gPS7YCGp_yqhfhN3jZ2A9BTwCPYlGba1tSaNBc1UW8XVHYkXv1b2lAg3LcbkaFSbvMSyArMKoKg1A=" rel="nofollow" target="_blank">sbloom@admabio.com</a></p> <p><strong>INVESTOR RELATIONS CONTACT:</strong><br>Michelle Pappanastos <br>Senior Managing Director, Argot Partners | 212-600-1902 | <a href="https://www.globenewswire.com/Tracker?data=cchedjd8ccsbPNbe0dletr6uGlHilDJHf-NquMLvdpMBhCEP3VUbyEzkB7jWdodkiXThJ9hzjlxw7OLbSDP_XwwFLDE-Ze4cjm_Bjdm_ApxG4IlHIgFp5HG0oPO9MGZB" rel="nofollow" target="_blank">michelle@argotpartners.com</a></p> <img class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=ODM5NDU5NiM0NTU1MzExIzIwMjM3MzA="> <br><img src="https://ml.globenewswire.com/media/MmFmYWY5NTctNmNiNC00ZWI1LTg3YTktM2NmY2ZkYWNlYzAxLTEwMzUyOTc=/tiny/ADMA-Biologics-Inc-.png"><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/468b61b4-73b9-495e-a4be-f4823782b2fd"><img src="https://ml.globenewswire.com/media/468b61b4-73b9-495e-a4be-f4823782b2fd/small/adma-biologics-rgb-l-092115p-jpg.jpg" border="0" width="150" height="52" alt="Primary Logo"></a></p> Source: ADMA Biologics, Inc. ]]> </content:encoded> </item> <item> <title>ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments</title> <link>https://www.admabiologics.com/investors/press-releases/detail/521/adma-biologics-reports-record-third-quarter-2021-financial</link> <pubDate>Wed, 10 Nov 2021 16:01:00 -0500</pubDate> <guid isPermaLink="true">https://www.admabiologics.com/investors/press-releases/detail/521/adma-biologics-reports-record-third-quarter-2021-financial</guid> <content:encoded> <![CDATA[ <p align="center"><em>Generated Record Total Revenues of $20.7 Million in the Third Quarter 2021, a 101% Increase Over Third Quarter 2020</em><br></p> <p align="center"><em>Achieved First-Time Positive Gross Profit</em></p> <p align="center"><em>Narrowed Net Losses Quarter-Over-Quarter </ ]]> <![CDATA[ em></p> <p align="center"><em>Management to Host Conference Call and Webcast Today at 4:30 p.m. ET</em></p> <p>RAMSEY, N.J. and BOCA RATON, Fla., Nov. 10, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported financial results for the three months ended September 30, 2021, its fiscal third quarter, and provided an overview of recent progress and accomplishments.</p> <p>“Achieving a positive gross profit and 101% year-over-year revenue growth represents a key inflection point for the Company as we continue our ongoing commercial and production ramp up. These financial milestones and accomplishments would not have been possible without the dedication and focus of ADMA’s staff, leadership and advisors. We commend the entire team for their extraordinary efforts focused on improving healthcare for U.S. patients,” said Adam Grossman, President and Chief Executive Officer of ADMA. “The investments we have made into our manufacturing facility and our ADMA BioCenters plasma collection operations are yielding positive results and we are encouraged by the contributions from each segment to our overall operations. Additionally, we strengthened our balance sheet with the recent closing of an underwritten public equity offering of $57.5 million in gross proceeds which, in combination with our active engagement with prospective debt lenders to raise additional non-dilutive capital has the potential to substantially fund our business to profitability no later than the first quarter of 2024.”</p> <p>Mr. Grossman continued, “During the third quarter, our inventory and property and equipment balances continued to grow, which will support the significant revenue growth we anticipate over the coming quarters. We believe our organization, through its operational execution, has clearly demonstrated strength and resilience, and is well-positioned to meet or exceed all previously disclosed financial targets and unlock significant value for stockholders in the periods ahead. The ADMA BioCenters segment continues to excel and remains on track to have 10 or more plasma collection facilities FDA-licensed by year-end 2023. The rapid expansion of our plasma collection center network, in addition to the yield enhancements from the implementation of Haemonetics’ Persona® technology, will firm up internal plasma self-sufficiency, help to insulate ADMA from the challenges presently impacting the broader plasma collection industry and ensure continuity of product supply for ADMA’s commercial immune globulin (IG) portfolio to assist in meeting the increasing prescriber demands in the growing U.S. IG market.”</p> <p>“The commercial, regulatory and operational milestones achieved during 2021 firmly establish ADMA as a vertically integrated, cGMP-compliant fractionator capable of successfully competing in the rapidly growing U.S. IG market. With the more substantive investments now behind the Company, the pathway to profitability is well-defined and rapidly approaching, and we continue to reiterate all previously communicated strategic and financial objectives. Looking forward, ADMA anticipates continued commercial execution and remains committed to unlocking the yet-to-be-realized fair value that this asset base now commands,” concluded Mr. Grossman.</p> <p><strong>Select Third Quarter 2021 Achievements &amp; Recent Corporate Developments:</strong></p> <ul type="disc"> <li> <strong>Continued Commercial Execution: </strong> <ul type="circle"> <li>Achieved record third quarter 2021 total revenues of $20.7 million, compared to $10.3 million for the third quarter of 2020, reflecting a 101% increase. </li> <li>Generated a positive gross profit for the first time in Company history, and successfully narrowed sequential net quarterly losses. <br><br> </li> </ul> </li> <li> <strong>Strengthened Cash Position.</strong> On October 25, 2021, ADMA closed an underwritten public offering, raising approximately $53.9 million, net of all underwriting discounts and expenses associated with the offering. ADMA continues to actively engage prospective debt lenders to potentially raise additional, non-dilutive capital, which if successful, has the potential to fund the Company to profitability.<br><br> </li> <li> <strong>Completed Multi-Year Supply Chain Robustness and Remediation Processes.</strong> In addition to the significant operating and cost efficiencies expected from the VanRx SA25 Workcell aseptic filling machine which was recently approved by the U.S. Food and Drug Administration (FDA), ADMA’s in-house fill-finish capabilities position the Company as the only U.S.-domiciled fractionator of plasma-derived products with complete end-to-end control of its critical manufacturing functions. The VanRx approval will also enable ADMA to explore potentially accretive contract manufacturing opportunities with third parties not currently contemplated in ADMA’s financial guidance. The Company will communicate contract manufacturing developments as appropriate. <br><br> </li> <li> <strong>Continued ADMA BioCenters Plasma Collection Network Expansion. </strong>ADMA currently has nine plasma collection facilities under its corporate umbrella at various stages of FDA approval and development, including five facilities that are currently operational and collecting plasma. The Company remains on track to have 10 or more plasma collection centers FDA-licensed by year-end 2023. The anticipated yield enhancement resulting from the recent Persona® implementation, in combination with the Company’s growing BioCenters network, has ADMA well-positioned to achieve source plasma self-sufficiency and contribute to quarter-over-quarter revenue and plasma collections growth throughout 2021 and beyond. These activities will help ensure continuity of commercial product supply to customers and patients in the growing U.S. IG market.<br><br> </li> <li> <strong>Strengthened Board of Directors. </strong>The appointment of Young T. Kwon, Ph.D. to its Board of Directors meaningfully strengthens ADMA’s ability to navigate the contours of the commercial IG landscape and effectively evaluate strategic business opportunities. Over the course of his career, Dr. Kwon has held a variety of C-suite leadership positions, in which he played pivotal roles involving multibillion-dollar mergers and acquisitions. Dr. Kwon recently served as Chief Financial and Business Officer of Momenta Pharmaceuticals, where he led the sale to Johnson &amp; Johnson for approximately $6.5 billion in 2020.<br><br> </li> <li> <strong>Demonstrated Commitment to Stockholders. </strong>As previously disclosed, ADMA has engaged Morgan Stanley as an advisor to evaluate a variety of strategic and financing alternatives. The evaluation of these alternatives as well as the formal engagement with Morgan Stanley demonstrates ADMA’s management and Board of Directors’ unwavering commitment to optimizing value for its stockholders.<br><br> </li> </ul> <p><strong>Third Quarter 2021 Financial Results </strong></p> <p>Total revenues for the quarter ended September 30, 2021 were approximately $20.7 million, compared to approximately $10.3 million for the quarter ended September 30, 2020, representing an increase of approximately $10.4 million, or 101%. The revenue growth for the quarter ended September 30, 2021, compared to the quarter ended September 30, 2020, was favorably impacted by the continued commercial ramp-up of ADMA’s intravenous immune globulin (IVIG) product portfolio and sale of intermediate fractions. Gross profit during the third quarter of 2021 was approximately $0.4 million compared to a gross loss of approximately $1.6 million for the three months ended September 30, 2020. The improved gross profit year-over-year was primarily attributable to increased sales of ADMA’s higher margin hyperimmune globulin product portfolio, along with a portion of the sales generated from conformance batches.</p> <p>Consolidated net loss was $17.7 million, or $0.13 per basic and diluted share, for the three months ended September 30, 2021, as compared to $16.9 million, or $0.19 per basic and diluted share, for the three months ended September 30, 2020. The $0.8 million increase in net loss was primarily due to the increased operating loss for the quarter of $0.6 million, as the improved revenues and gross profit were more than offset by increases in plasma center operating expenses and selling, general administrative expenses, and to the increase in interest expense.</p> <p>At September 30, 2021, ADMA had cash and cash equivalents of approximately $34.4 million and accounts receivable of approximately $20.4 million, compared to cash and cash equivalents of approximately $55.9 million and accounts receivable of approximately $13.2 million as of December 31, 2020. Subsequent to the end of the third quarter, on October 25, 2021, the Company closed an underwritten public offering whereby the Company received gross proceeds of $57.5 million, amounting to net proceeds, after deducting underwriting discounts and expenses associated with the offering, of approximately $53.9 million.</p> <p><strong>Conference Call Information</strong></p> <p>ADMA will host a conference call today, November 10, 2021, at 4:30 p.m. Eastern Time, to discuss the fiscal third quarter 2021 financial results and recent corporate updates. To access the conference call, please dial (855) 884-8773 (local) or (615) 622-8043 (international) at least 10 minutes prior to the start time and refer to conference ID 4459844. A live audio webcast of the call will be available under "Events &amp; Webcasts" in the Investor section of the Company's website, <a href="https://www.globenewswire.com/Tracker?data=-XtmmJC1TnEeURAAIulQTeakFyeZDACAbjtTAV_PeCLIJoYErEK-5BTct37_8qAyAAOvJFieiCn1yMXMUgcNptMvrJAi5KkBYe88_G91Ml31hzCZdTbe2MTHW0Dav4TTGA3M_khvF9G6q4ChQHJYSQ==" rel="nofollow" target="_blank">https://ir.admabiologics.com/events-webcasts</a>. An archived webcast will be available on the Company's website approximately two hours after the event.</p> <p align="justify"><strong>About ADMA BioCenters</strong></p> <p align="justify">ADMA BioCenters operates FDA-licensed facilities specializing in the collection of human plasma used to make special medications for the treatment and prevention of certain infectious diseases. Managed by a team of experts who have decades of experience in the specialized field of plasma collection, ADMA BioCenters provides a safe, professional and pleasant donation environment. ADMA BioCenters strictly follows FDA regulations and guidance and enforces current good manufacturing practices (cGMP) in all of its facilities. For more information about ADMA BioCenters, please visit www.admabiocenters.com.</p> <p align="justify"><strong>About ADMA Biologics, Inc. (ADMA) </strong></p> <p align="justify">ADMA is an end-to-end American commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three FDA-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM® (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the Hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=gRivIp2VYH3aooaGGQYetfb2XlGZxIs63xq7SI4zjfEpXT-HW5WsOhOsHiC12v4kox6Tk7oIMOK6v9T_Dw4PZiszCxYukGV8lokFtDeSb4o=" rel="nofollow" target="_blank">www.admabiologics.com</a>.</p> <p align="justify"><strong>Cautionary Note Regarding Forward-Looking Statements </strong></p> <p align="justify"><em>This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 about ADMA Biologics, Inc. and its subsidiaries (collectively, “we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “potential,” “planning,” “expect,” “believe,” “will,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements also include, but are not limited to, statements about ADMA’s future results of operations, including our anticipated timing for reaching profitability; execution of the Company’s commercial goals; the Company’s ability to refinance and expand its senior credit facility; expected benefits from the VanRx aseptic fill-finish machine, including operating and cost efficiencies and contract manufacturing opportunities; the anticipated benefits from the recent implementation of Haemonetics’ Persona® technology combined with our plasma collection center network; the goal of having 10 or more FDA-licensed plasma collection centers by year-end 2023; the Company’s plasma collections and production; and our ability to maintain sufficient plasma supply. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.</em></p> <p><strong>COMPANY CONTACT: </strong><br>Skyler Bloom <br>Director, Investor Relations and Corporate Strategy | 201-478-5552 | <a href="https://www.globenewswire.com/Tracker?data=E1QVVtE7Bh-Wbtq6DVXrv3g1x0PFszS2t1OMhpN_A1EEFHw1Ithe-7_A_E1z-EWOf-uIn0CmpPJHJR7tKDcI3RP8UD4Da4Pl_TtYpsJbnDA=" rel="nofollow" target="_blank">sbloom@admabio.com</a></p> <p><strong>INVESTOR RELATIONS CONTACT:</strong><br>Michelle Pappanastos <br>Senior Managing Director, Argot Partners | 212-600-1902 | <a href="https://www.globenewswire.com/Tracker?data=K_k2x3-XiUCuPgr5uw8MXcO7baK787EPLa2pOyr5SrGDGs2U5XfrR40zCHXRq6YAHwx6O0zvZwQmMV7VESg0c_2d_HUumxcKEh5l7oRgoow1Dv5v33Vk5wNwMOUg1zdo" rel="nofollow" target="_blank">michelle@argotpartners.com</a></p> <p align="center"><strong><br></strong></p> <p align="center"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p> <p align="center"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS</strong></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"> <tr> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="7" style="border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>Three Months Ended September 30,</strong></td> <td style="vertical-align: bottom ; "> </td> <td colspan="7" style="border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>Nine Months Ended September 30,</strong></td> </tr> <tr> <td style="max-width:44%; width:44%; min-width:44%;;vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:11%; width:11%; min-width:11%;;border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>2021</strong></td> <td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:11%; width:11%; min-width:11%;;border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>2020</strong></td> <td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:11%; width:11%; min-width:11%;;border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>2021</strong></td> <td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:11%; width:11%; min-width:11%;;border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>2020</strong></td> <td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: center ; vertical-align: middle; vertical-align: bottom ; ">(Unaudited)</td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: center ; vertical-align: middle; vertical-align: bottom ; ">(Unaudited)</td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; "><strong>REVENUES:</strong></td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Product revenue</td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">20,644,842</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">10,240,650</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">54,452,633</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">28,156,571</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">License revenue</td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">35,708</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">35,708</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">107,125</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">107,125</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 20.0px; vertical-align: bottom ; "><strong>Total revenues</strong></td> <td style="vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">20,680,550</td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">10,276,358</td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">54,559,758</td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">28,263,696</td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; "><strong>OPERATING EXPENSES:</strong></td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Cost of product revenue (exclusive of amortization expense shown below)</td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">20,295,213</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">11,855,464</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">56,897,959</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">42,180,319</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Research and development</td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">770,557</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,708,391</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">2,917,072</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">4,893,549</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Plasma center operating expenses</td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">3,146,221</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,218,898</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">8,191,890</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">2,597,444</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Amortization of intangible assets</td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">178,838</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">178,838</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">536,514</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">536,514</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Selling, general and administrative</td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">10,726,797</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">9,115,744</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">31,198,880</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">25,750,458</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 20.0px; vertical-align: bottom ; "><strong>Total operating expenses</strong></td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">35,117,626</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">24,077,335</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">99,742,315</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">75,958,284</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; "><strong>LOSS FROM OPERATIONS</strong></td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(14,437,076</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(13,800,977</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(45,182,557</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(47,694,588</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; "><strong>OTHER INCOME (EXPENSE):</strong></td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Interest income</td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">4,256</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,164</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">32,241</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">268,643</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Interest expense</td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(3,298,680</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(3,091,200</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(9,741,110</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(8,875,597</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Other expense</td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">18,546</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(26,440</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(106,772</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(39,232</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 20.0px; vertical-align: bottom ; "><strong>Other expense, net</strong></td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(3,275,878</td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(3,116,476</td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(9,815,641</td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(8,646,186</td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> </tr> <tr> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; "><strong>NET LOSS</strong></td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(17,712,954</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(16,917,453</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(54,998,198</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(56,340,774</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; "><strong>BASIC AND DILUTED LOSS PER COMMON SHARE</strong></td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(0.13</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(0.19</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(0.44</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(0.68</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; "><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</strong></td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; "><strong>Basic and Diluted</strong></td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">133,770,147</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">87,698,258</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">125,682,400</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">82,627,753</td> <td style="border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> </tr> </table> <p align="center"><strong><br>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p> <p align="center"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS</strong></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"> <tr> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>September 30,</strong></td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>December 31,</strong></td> </tr> <tr> <td style="max-width:73%; width:73%; min-width:73%;;vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:11%; width:11%; min-width:11%;;border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>2021</strong></td> <td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:11%; width:11%; min-width:11%;;border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>2020</strong></td> <td style="max-width:1%; width:1%; min-width:1%;;border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: center ; vertical-align: middle; vertical-align: bottom ; ">(Unaudited)</td> <td style="text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; "><strong>ASSETS</strong></td> <td colspan="3" style="text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; ">Current assets:</td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Cash and cash equivalents</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">34,410,570</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">55,921,152</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Accounts receivable, net</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">20,392,621</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">13,237,290</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Inventories</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">114,122,873</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">81,535,599</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Prepaid expenses and other current assets</td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">5,859,046</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">3,046,466</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 25.0px; vertical-align: bottom ; ">Total current assets</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">174,785,110</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">153,740,507</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; ">Property and equipment, net</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">48,393,723</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">41,593,090</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; ">Intangible assets, net</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,907,607</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">2,444,121</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; ">Goodwill</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">3,529,509</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">3,529,509</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; ">Right to use assets</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">6,690,943</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">4,259,191</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; ">Deposits and other assets</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">3,333,514</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">2,106,976</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; "><strong>TOTAL ASSETS</strong></td> <td style="border-top: solid black 1pt ; border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="border-top: solid black 1pt ; border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">238,640,406</td> <td style="border-top: solid black 1pt ; border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="border-top: solid black 1pt ; border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">207,673,394</td> <td style="border-top: solid black 1pt ; border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; "><strong>LIABILITIES AND STOCKHOLDERS' EQUITY</strong></td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; ">Current liabilities:</td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Accounts payable</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">17,282,841</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">11,073,708</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Accrued expenses and other current liabilities</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">14,410,329</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">8,365,143</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Current portion of deferred revenue</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">142,834</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">142,834</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">Current portion of lease obligations</td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">501,239</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">365,682</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 20.0px; vertical-align: bottom ; ">Total current liabilities</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">32,337,243</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">19,947,367</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; ">Senior notes payable, net of discount</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">94,363,008</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">92,968,866</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; ">Deferred revenue, net of current portion</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">2,011,573</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">2,118,698</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; ">Lease obligations, net of current portion</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">6,915,750</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">4,334,151</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; ">Other non-current liabilities</td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">232,665</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">54,886</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; "><strong>TOTAL LIABILITIES</strong></td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">135,860,239</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">119,423,968</td> <td style="border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; "><strong>COMMITMENTS AND CONTINGENCIES</strong></td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; "><strong>STOCKHOLDERS' EQUITY</strong></td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; ">Preferred Stock, $0.0001 par value, 10,000,000 shares authorized,</td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">no shares issued and outstanding</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">-</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">-</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; ">Common Stock - voting, $0.0001 par value, 300,000,000 and 150,000,000 shares authorized,</td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="3" style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 10.0px; vertical-align: bottom ; ">131,872,026 and 104,902,888 shares issued and outstanding</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">13,831</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">10,490</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; ">Additional paid-in capital</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">498,229,637</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">428,704,039</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; ">Accumulated deficit</td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(395,463,301</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">(340,465,103</td> <td style="padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; ">)</td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; "><strong>TOTAL STOCKHOLDERS' EQUITY</strong></td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">102,780,167</td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">88,249,426</td> <td style="border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="text-align: left ; vertical-align: middle; vertical-align: bottom ; "><strong>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</strong></td> <td style="border-top: solid black 1pt ; border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="border-top: solid black 1pt ; border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">238,640,406</td> <td style="border-top: solid black 1pt ; border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="border-top: solid black 1pt ; border-bottom: double 15px 3pt ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">$</td> <td style="border-top: solid black 1pt ; border-bottom: double 15px 3pt ; padding-left: 0 ; padding-right: 0 ; text-align: right ; vertical-align: middle; vertical-align: bottom ; ">207,673,394</td> <td style="border-top: solid black 1pt ; border-bottom: double 15px 3pt ; padding-left: 0 ; text-align: left ; vertical-align: middle; vertical-align: bottom ; "> </td> </tr> <tr> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> <td style="vertical-align: bottom ; "> </td> <td colspan="3" style="vertical-align: bottom ; "> </td> </tr> </table> <img class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=ODM5MTM3OCM0NTQzMjk3IzIwMjM3MzA="> <br><img src="https://ml.globenewswire.com/media/ZWVmOTRiYjctOTY0My00NmYzLTliOTYtOGU2YTM0ZDI4NzNlLTEwMzUyOTc=/tiny/ADMA-Biologics-Inc-.png"><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/468b61b4-73b9-495e-a4be-f4823782b2fd"><img src="https://ml.globenewswire.com/media/468b61b4-73b9-495e-a4be-f4823782b2fd/small/adma-biologics-rgb-l-092115p-jpg.jpg" border="0" width="150" height="52" alt="Primary Logo"></a></p> Source: ADMA Biologics, Inc. ]]> </content:encoded> </item> <item> <title>ADMA Biologics to Report Third Quarter 2021 Financial Results on November 10, 2021</title> <link>https://www.admabiologics.com/investors/press-releases/detail/520/adma-biologics-to-report-third-quarter-2021-financial</link> <pubDate>Wed, 03 Nov 2021 07:00:00 -0400</pubDate> <guid isPermaLink="true">https://www.admabiologics.com/investors/press-releases/detail/520/adma-biologics-to-report-third-quarter-2021-financial</guid> <content:encoded> <![CDATA[ <h3 class="spr-ir-news-article-title">Conference Call Scheduled for November 10, 2021 at 4:30 p.m. ET</h3> <p align="left">RAMSEY, N.J. and BOCA RATON, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the third quarter ended September 30, 2021 on Wednesday, November 10, 2021 after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.<br></p> <p>To access the conference call, please dial (855) 884-8773 (local) or (615) 622-8043 (international) at least 10 minutes prior to the start time and refer to conference ID 4459844. A live audio webcast of the call will be available under “Events &amp; Webcasts” in the investor section of the Company’s website, <a href="https://www.globenewswire.com/Tracker?data=GT31fEOTtfg_XXf-rdgmysPRUmHmBkrEK3pimbiM8WvV7Rj46cGhmthxreqniFKMbsKU6e8B8kM-DvcVYKWUpDFPctlm_rfeCNfWe9xOQkL797yTHAXnCZn-tNZGwOby1Gu3WOUBUHt9bowuOgEMGA==" rel="nofollow" target="_blank">https://ir.admabiologics.com/events-webcasts</a>. An archived webcast will be available on the Company’s website approximately two hours after the event.</p> <p align="justify"><strong>About ADMA Biologics, Inc. (ADMA)</strong></p> <p align="justify">ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=wYsW09CeER77l3Wq5-8zw58rYxCCjyxd4kvPhtyQRKk61vwdu-NUDDQU1xyxPqRAxMEMHGxTGTpltys1Dmedx8wPXPh9NVpyNsDO7f8E0RQhlelRYZ13ywM35E40OXrU5xvHK4PI43fd4NXf_x-lFb06hIt-IqfkmlTWvOwRzn1jq30-_soucjOSYLRZYLT3aP8tm4e0Oa6_wShwRkbH0-56Bn4Lw8aZbVojNHBGDYhjLXdhRl1EARRuLs0ocJlUfoXgHbObKj7lIOn6tXdTlA==" rel="nofollow" target="_blank">www.admabiologics.com</a>.</p> <p align="justify"><strong>COMPANY CONTACT: </strong><br>Skyler Bloom<br>Director, Investor Relations and Corporate Strategy | 201-478-5552 | <a href="https://www.globenewswire.com/Tracker?data=ymja6UoIT7VlGgZ1HfNzQ8UYM2qhJ0eRFEka9bDUVlOi5JJEnDbZGl5OK7UvjR82dWwZXEiXhcfBwnP75i5PvNYW6sJJxOBVkQ0pm4McaE8=" rel="nofollow" target="_blank">sbloom@admabio.com</a> </p> <p align="justify"><strong>INVESTOR RELATIONS CONTACT:</strong><br>Michelle Pappanastos <br>Senior Managing Director, Argot Partners | 212-600-1902 | <a href="https://www.globenewswire.com/Tracker?data=j07d35mTBniboWQmNzWEsixjeE9htHe3T3OaayvJdsvOWQldi16Z4dfuqLslWFWBUdJc8MJ2tZSYiksSP30f8sKl1uDx_OS3ph-yek4IS4LTmDdO_hxqCSEM1vRO6lmz" rel="nofollow" target="_blank">michelle@argotpartners.com</a> </p> <img class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=ODM4NTAzMyM0NTI4MzM5IzIwMjM3MzA="> <br><img src="https://ml.globenewswire.com/media/OGFjM2I3YjYtZGZjMC00YWZmLWI0YjgtMmMwZmUzZjQzNmE2LTEwMzUyOTc=/tiny/ADMA-Biologics-Inc-.png"><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/468b61b4-73b9-495e-a4be-f4823782b2fd"><img src="https://ml.globenewswire.com/media/468b61b4-73b9-495e-a4be-f4823782b2fd/small/adma-biologics-rgb-l-092115p-jpg.jpg" border="0" width="150" height="52" alt="Primary Logo"></a></p> Source: ADMA Biologics, Inc. ]]> </content:encoded> </item> <item> <title>ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares</title> <link>https://www.admabiologics.com/investors/press-releases/detail/519/adma-biologics-announces-closing-of-57-5-million-public</link> <pubDate>Mon, 25 Oct 2021 16:01:00 -0400</pubDate> <guid isPermaLink="true">https://www.admabiologics.com/investors/press-releases/detail/519/adma-biologics-announces-closing-of-57-5-million-public</guid> <content:encoded> <![CDATA[ <p align="left">RAMSEY, N.J. and BOCA RATON, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its ]]> <![CDATA[ previously announced underwritten public offering of 50 million shares of its common stock at a public offering price of $1.00 per share, in addition to the exercise in full of the underwriters’ option to purchase an additional 7.5 million shares of common stock. The gross proceeds from the exercise of the overallotment option were $7.5 million, bringing the total gross proceeds to ADMA from the offering to $57.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses.<br></p> <p>ADMA intends to use the net proceeds from this offering (i) to advance the commercial sales of its U.S. Food and Drug Administration (FDA)-approved products through the procurement of raw materials for the manufacturing of BIVIGAM<sup>®</sup> and ASCENIV™; (ii) to expand its plasma collection facility network; (iii) to scale up the manufacturing capacity of its Boca Raton facility and to make continuous improvements in order to adhere to current Good Manufacturing Practice (cGMP) compliance; (iv) to explore business development opportunities; and (v) for general corporate purposes and other capital expenditures.</p> <p>Raymond James &amp; Associates, Inc. and Cantor Fitzgerald &amp; Co. acted as joint book-running managers for the offering.</p> <p>The offering of the securities described above was made by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-256643) previously filed with the Securities and Exchange Commission (“SEC”) and declared effective on August 3, 2021. The final prospectus supplement and the accompanying prospectus relating to the offering was filed with the SEC on October 21, 2021 and is available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Raymond James &amp; Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, or by telephone at (800) 248-8863, or e-mail at prospectus@raymondjames.com, or from Cantor Fitzgerald &amp; Co., Attn: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022 or by e-mail at prospectus@cantor.com.</p> <p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p> <p align="justify"><strong>About ADMA Biologics, Inc. (ADMA) </strong></p> <p align="justify">ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM<sup>®</sup> (immune globulin intravenous, human) for the treatment of PI; and NABI-HB<sup>®</sup> (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=B1d52bRALL7IBce-9rcu32LuzElQA1XpAQX_1W_PtkiczrTa0TigC00XNmr-JM3qdw2XGwBNZJYzoQPMyZ9oXZgCZguN7qs1umQ9WGvpoHr0hloVFl-phWjbzTvy9mr1PYvJd-TImDgnqfObds-7wZ2lKQqiw4eyG5uE1sD-8o87s-xC-eV8k0q8zL6otwqxkdXhkLqbVQyLiJmNPKVv4irDjhRd4em-MEMhO1IOdfYb71GRgwhxOpGA-EqKFm5zINPA1MclCMaRECbNzLmk6w==" rel="nofollow" target="_blank">www.admabiologics.com</a>.</p> <p align="justify"><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p> <p align="justify"><em>This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include statements about ADMA’s intended use of proceeds generated from the offering. Actual events or results may differ materially from those described in this document due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering and the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.</em></p> <p align="justify"><strong>COMPANY CONTACT: </strong><br>Skyler Bloom<br>Director, Investor Relations and Corporate Strategy | 201-478-5552 | <a href="https://www.globenewswire.com/Tracker?data=kqRcKPKotw0i_W-ODi4_6z2gvEdpXSZ7RJ1FR6VMIBx7Mfc-vHRf8n5E5IwkqoUsc93padpl8OsP91dkuZgtPdnqgkYNLmQxKJ6tcVmHaDA=" rel="nofollow" target="_blank">sbloom@admabio.com</a></p> <p align="justify"><strong>INVESTOR RELATIONS CONTACT:</strong><br>Michelle Pappanastos <br>Senior Managing Director, Argot Partners | 212-600-1902 | <a href="https://www.globenewswire.com/Tracker?data=p4aN5pwZIY-r0maFC24K-KT14d4ZZ8aWGAa13LI1w5ZcpIZRuNfn5iMFRcULP7RzSMkLTo1qeUyXNe1HTSgQ26jvys5L3FfUSgde9H4VZl8=" rel="nofollow" target="_blank">michelle@argotpartners.com</a></p> <p></p> <img class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=ODM3OTM0NyM0NTEyMTkxIzIwMjM3MzA="> <br><img src="https://ml.globenewswire.com/media/M2ZlNzA4N2UtYTc2MC00ZTQ0LTljMDktNWNiOTJhM2Y2ZDQzLTEwMzUyOTc=/tiny/ADMA-Biologics-Inc-.png"><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/468b61b4-73b9-495e-a4be-f4823782b2fd"><img src="https://ml.globenewswire.com/media/468b61b4-73b9-495e-a4be-f4823782b2fd/small/adma-biologics-rgb-l-092115p-jpg.jpg" border="0" width="150" height="52" alt="Primary Logo"></a></p> Source: ADMA Biologics, Inc. ]]> </content:encoded> </item> <item> <title>ADMA Biologics Announces Data Presented at the 2021 ISIRV-WHO Conference</title> <link>https://www.admabiologics.com/investors/press-releases/detail/518/adma-biologics-announces-data-presented-at-the-2021</link> <pubDate>Fri, 22 Oct 2021 07:00:00 -0400</pubDate> <guid isPermaLink="true">https://www.admabiologics.com/investors/press-releases/detail/518/adma-biologics-announces-data-presented-at-the-2021</guid> <content:encoded> <![CDATA[ <p align="left">RAMSEY, N.J. and BOCA RATON, Fla., Oct. 22, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that a poster presentation was made at the virtual 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization (ISIRV-WHO) Conference. The abstract and poster presentation detailed the use of ASCENIV<sup> TM</sup>, a novel intravenous immune globulin (IGIV) human-slra, as concomitant therapy in a 70-year-old African American male with a history of bronchiectasis who presented with severe respiratory viral disease and confirmed COVID-19 infection.<br></p> <p>In the abstract and poster presentation, ADMA described the use of ASCENIV as concomitant therapy in an adult hospitalized with COVID-19 infection and rapidly progressive acute respiratory distress syndrome (ARDS). A 70-year-old African American male with history of bronchiectasis presented to the emergency department with a one-week history of increasing dyspnea, dry cough, sudden onset of high-grade fevers, and body chills. The patient was initiated on broad-spectrum anti-infectives and steroids. Initial blood chemistries were unremarkable, pan cultures were negative but a COVID-19 diagnostic was confirmed positive. The patient’s respiratory status deteriorated over the next week with continued progression of pneumonia requiring mechanical ventilation. On Day 11, the patient was initiated on ASCENIV at 1500 mg/kg. In the days following, the patient developed high-grade fevers, prompting modification of anti-infectives and a second dose of ASCENIV at 750 mg/kg. Over the next several days, respiratory function improved, prompting extubation, but complications with a bout of severe tachypnea and declined respiratory function led to temporary re-intubation. With continued clinical management, the patient’s respiratory status steadily improved, warranting extubation and transition to rehabilitation with a confirmed negative COVID-19 test result, no documented co-infections, reduced inflammatory markers, and recovery of lung function.</p> <p>This case documents the clinical outcome of a multi-modality therapeutic approach with broad-spectrum anti-infectives and concomitant ASCENIV (IVIG human-slra) utilization for the management of severe respiratory infection. Further investigation is warranted to evaluate the use of ASCENIV as adjunctive therapy in vulnerable and immune compromised patients with severe respiratory disease.</p> <p><strong>Abstract Title:</strong><em> Clinical Impact of Concomitant Use of a Novel High-Titer Immune Globulin in an Adult with COVID-19 and Severe Acute Respiratory Distress Syndrome (ARDS)</em></p> <p><strong>Authors:</strong> Gene A. Wetzstein, PharmD, BCOP; Mourad Ismail, MD; Jeffrey Gruenglas, DHSc(c), MBE, MA; Dima A. Decker, PhD; James Mond, MD, PhD</p> <p><strong>Dates: </strong>October 19-22, 2021</p> <p><strong>Poster Number:</strong> 124</p> <p align="justify"><strong>About ADMA Biologics, Inc. (ADMA)</strong></p> <p align="justify">ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=a2FNs0skbZhopL70zXzKiq2LEKb-bdmZZd2wWWhPijWuVSJu1lrxgP2atEp62jxTnoZ20MunsMeizx3rYM9pZTRdp48Lv3y7yIWbHPnyBWo=" rel="nofollow" target="_blank">www.admabiologics.com</a>.<br><br><strong>About ASCENIV™</strong></p> <p align="justify">ASCENIV (immune globulin intravenous, human – slra 10% liquid) is a plasma-derived, polyclonal, intravenous IVIG. ASCENIV was approved by the United States Food and Drug Administration (FDA) in April 2019 and is indicated for the treatment of primary humoral immunodeficiency (PI), also known as primary immune deficiency disease (PIDD), in adults and adolescents (12 to 17 years of age). ASCENIV is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and respiratory syncytial virus (RSV) plasma obtained from donors tested using the Company’s proprietary microneutralization assay. ASCENIV contains naturally occurring polyclonal antibodies, which are proteins that are used by the body’s immune system to neutralize microbes, such as bacteria and viruses and prevent against infection and disease. ASCENIV is protected by U.S. Patents: 9,107,906, 9,714,283 and 9,815,886. Certain data and other information about ASCENIV can be found by visiting <a href="https://www.globenewswire.com/Tracker?data=XVp9rHo6xkR_al0g-CuGbu5zPDw2rrChdcJ4h5Xno7qZIJnREGjIM3EoNS04ZdSaM4YjWJvx6ug5w6PNinv4Ng==" rel="nofollow" target="_blank">www.asceniv.com</a>. Information about ADMA and its products can be found on the Company’s website at www.admabiologics.com.</p> <p align="justify"><strong>Additional Important Safety Information about ASCENIV™</strong></p> <p align="justify">ASCENIV™ (immune globulin intravenous, human – slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"> <tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; ">WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE</td></tr> <tr><td style="border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; "> </td></tr> <tr><td style="border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; ">Thrombosis may occur with immune globulin (IGIV) products, including ASCENIV™. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.</td></tr> <tr><td style="border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; "> </td></tr> <tr><td style="border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; ">Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients.</td></tr> <tr><td style="border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; "> </td></tr> <tr><td style="border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; ">Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. ASCENIV™ does not contain sucrose.</td></tr> <tr><td style="border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; "> </td></tr> <tr><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; ">For patients at risk of thrombosis, renal dysfunction or renal failure, administer ASCENIV™ at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.</td></tr> </table> <p align="justify"><br>ASCENIV™ is contraindicated in:</p> <ul type="disc"> <li style="margin-top:13.5pt; margin-bottom:13.5pt; text-align:justify;">Patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin.</li> <li style="margin-top:13.5pt; margin-bottom:13.5pt; text-align:justify;">IgA-deficiency patients with antibodies to IgA and a history of hypersensitivity.</li> </ul> <p align="justify"><strong>Warnings and Precautions</strong></p> <p align="justify">Severe hypersensitivity reactions may occur with IGIV products, including ASCENIV™. In case of hypersensitivity, discontinue ASCENIV™ infusion immediately and institute appropriate treatment. Medications such as epinephrine should be available for treatment of acute hypersensitivity reactions.</p> <p align="justify">Thrombosis may occur following treatment with immunoglobulin products, including ASCENIV™. Thrombosis may occur in the absence of known risk factors.</p> <p align="justify">Acute renal dysfunction/failure, osmotic nephrosis, and death may occur upon use of human IGIV products. Ensure that patients are not volume depleted before administering ASCENIV™. Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure.</p> <p align="justify">Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IGIV treatment, including ASCENIV™.</p> <p align="justify">Aseptic meningitis syndrome (AMS) may occur with IGIV treatments, including ASCENIV™. AMS may occur more frequently in association with high doses (2 g/kg) and/or rapid infusion of IGIV.</p> <p align="justify">IGIV products, including ASCENIV™, may contain blood group antibodies that can act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin reaction and hemolysis.</p> <p align="justify">Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and the patient’s serum.</p> <p align="justify">Because ASCENIV™ is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.</p> <p align="justify">Periodic monitoring of renal function and urine output is particularly important in patients at increased risk of developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of ASCENIV™ and at appropriate intervals thereafter.</p> <p align="justify">After infusion of immunoglobulin, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs’) test.</p> <p align="justify"><strong>Adverse Reactions</strong></p> <p align="justify">The most common adverse reactions to ASCENIV™ (≥5% of study subjects) were headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea.</p> <p align="justify"><strong>You are encouraged to report side effects of prescription drugs to ADMA Biologics @ 1-800-458-4244 or the FDA. Visit </strong><a href="https://www.globenewswire.com/Tracker?data=A9MFaTRMxrrkF4div2x36upqE0xcg2xvNXGpsyxtIo6QqHIcEqUPhfIgvO68OWyScq6CDJlSQ46-pFPvrtxL-5-z4mwq4A6xsO8hTMn4MFDCm2pc2JDGIUPpvXssIDo19syRds2_t1tfQL4hdDL7TVCJ9yVnaI9AupCfoPn6Ne0eRzlZUzIrnvCKkWIwEQc2" rel="nofollow" target="_blank">www.fda.gov/MedWatch</a><strong> or call 1-800-FDA-1088.</strong></p> <p align="justify"><strong>COMPANY CONTACT: </strong><br>Skyler Bloom<br>Director, Investor Relations and Corporate Strategy | 201-478-5552 | <a href="https://www.globenewswire.com/Tracker?data=ZbAL1CDRF7PPm802OXsfWs6oLqys78Ze6meur3fyzFWla9MlpJ3Gien9Wb_VBUloEN0gCM7biUI7zeHrB_jZOxJsnzSsIFqO3wjt7WIQVOE=" rel="nofollow" target="_blank">sbloom@admabio.com</a></p> <p align="justify"><strong>INVESTOR RELATIONS CONTACT:</strong><br>Michelle Pappanastos <br>Senior Managing Director, Argot Partners | 212-600-1902 | <a href="https://www.globenewswire.com/Tracker?data=vXmWo21cnbkqdB9UDatrlV55TrK7jPmQHXOiS759Yei1tTcETaQ2GJoMLDLFvqo4wzw7RhuEdc7VizqVnYjoOL-uF76TVHIR1Vp_4JIf-duBL2dWoTZu9ft3MMveosr9" rel="nofollow" target="_blank">michelle@argotpartners.com</a></p> <p> <br></p> <img class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=ODM3Nzk0MSM0NDk4MDU2IzIwMjM3MzA="> <br><img src="https://ml.globenewswire.com/media/M2MyN2E0MDAtNDQyOC00YzY0LTliNTItNzQ2YTAwMmI0YTQ3LTEwMzUyOTc=/tiny/ADMA-Biologics-Inc-.png"><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/468b61b4-73b9-495e-a4be-f4823782b2fd"><img src="https://ml.globenewswire.com/media/468b61b4-73b9-495e-a4be-f4823782b2fd/small/adma-biologics-rgb-l-092115p-jpg.jpg" border="0" width="150" height="52" alt="Primary Logo"></a></p> Source: ADMA Biologics, Inc. ]]> </content:encoded> </item> <item> <title>ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock</title> <link>https://www.admabiologics.com/investors/press-releases/detail/517/adma-biologics-announces-pricing-of-public-offering-for-50</link> <pubDate>Thu, 21 Oct 2021 09:00:00 -0400</pubDate> <guid isPermaLink="true">https://www.admabiologics.com/investors/press-releases/detail/517/adma-biologics-announces-pricing-of-public-offering-for-50</guid> <content:encoded> <![CDATA[ <p align="left">RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced underwritten public offering of 50 million shares of its common stock at a public offering price of $1.00 per share, resulting in gross proceeds of approximately $50 million before deducting underwriting discounts and commissions and other estimated offering expenses.<br></p> <p>The offering is expected to close on October 25, 2021, subject to the satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to 7.5 million additional shares of common stock at the public offering price before deducting underwriting discounts and commissions.</p> <p>ADMA intends to use the net proceeds from this offering (i) to advance the commercial sales of its U.S. Food and Drug Administration (FDA)-approved products through the procurement of raw materials for the manufacturing of BIVIGAM® and ASCENIV™; (ii) to expand its plasma collection facility network; (iii) to scale up the manufacturing capacity of its Boca Raton facility and to make continuous improvements in order to adhere to current Good Manufacturing Practice (cGMP) compliance; (iv) to explore business development opportunities; and (v) for general corporate purposes and other capital expenditures.</p> <p>Raymond James &amp; Associates, Inc. and Cantor Fitzgerald &amp; Co. are acting as joint book-running managers for the offering.</p> <p>The securities described above are being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-256643) previously filed with the Securities and Exchange Commission (“SEC”) and declared effective on August 3, 2021. A preliminary prospectus supplement relating to the offering was filed with the SEC on October 20, 2021 and is available on the SEC’s website at www.sec.gov. The final prospectus supplement relating to the offering will be filed with the SEC and will also be available on the SEC’s web site at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Raymond James &amp; Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, or by telephone at (800) 248-8863, or e-mail at prospectus@raymondjames.com, or from Cantor Fitzgerald &amp; Co., Attn: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022 or by email at prospectus@cantor.com.</p> <p>Before investing in the offering, you should read in their entirety the preliminary prospectus supplement and its accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in the prospectus supplement and its accompanying prospectus, which provide more information about the Company and the offering.</p> <p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p> <p align="justify"><strong>About ADMA Biologics, Inc. (ADMA) </strong></p> <p align="justify">ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=8kiNIsEkUVvshEEhAkUJUXMA2m9CBTRnnqkdQm3P_zGMVhD7SnUDdZmkWUrAwRC5Dt-N19Pkq_sQfvyzVD4JuuqrsL0hBopa1JDUFA9prF4=" rel="nofollow" target="_blank">www.admabiologics.com</a>. </p> <p align="justify"><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p> <p align="justify"><em>This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include statements about the offering and ADMA’s intended use of proceeds generated from the offering. Actual events or results may differ materially from those described in this document due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering and the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.</em></p> <p><strong>COMPANY CONTACT:</strong><br>Skyler Bloom<br>Director, Investor Relations and Corporate Strategy | 201-478-5552 | <a href="https://www.globenewswire.com/Tracker?data=hxSG83KjtBOp53__SAkbtalIcCk514Cfv-yXTsjhocJroKbywbI_bHk-uyzZWBjWjVK_FYlHWHpVElII52Cf-rG2DNIS7r3W-OyKay6pajU=" rel="nofollow" target="_blank">sbloom@admabio.com</a> </p> <p><strong>INVESTOR RELATIONS CONTACT:</strong><br>Michelle Pappanastos<br>Senior Managing Director, Argot Partners | 212-600-1902 | <a href="https://www.globenewswire.com/Tracker?data=9rI5di_Nluj4rwIqX1BZyBpe-O7S3GAfIBTIUZe9_6LK2Rn9YwmigMZ8WGlVTa4x4cxJ7q-Xik-GHvQUhPjQT-sYLj3fzxw1OHPfmVL-ucLhQk3DL7rV5bgCoKw2VM9R" rel="nofollow" target="_blank">michelle@argotpartners.com</a> </p> <p> <br></p> <img class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=ODM3NzU3MiM0NDk2OTcyIzIwMjM3MzA="> <br><img src="https://ml.globenewswire.com/media/NGMxNGZiMmUtYzM4NC00ODNkLTlkMjUtNjBkZWMyZDgyMWZjLTEwMzUyOTc=/tiny/ADMA-Biologics-Inc-.png"><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/468b61b4-73b9-495e-a4be-f4823782b2fd"><img src="https://ml.globenewswire.com/media/468b61b4-73b9-495e-a4be-f4823782b2fd/small/adma-biologics-rgb-l-092115p-jpg.jpg" border="0" width="150" height="52" alt="Primary Logo"></a></p> Source: ADMA Biologics, Inc. ]]> </content:encoded> </item> <item> <title>ADMA Biologics Announces Proposed Public Offering of Common Stock</title> <link>https://www.admabiologics.com/investors/press-releases/detail/516/adma-biologics-announces-proposed-public-offering-of-common</link> <pubDate>Wed, 20 Oct 2021 16:01:00 -0400</pubDate> <guid isPermaLink="true">https://www.admabiologics.com/investors/press-releases/detail/516/adma-biologics-announces-proposed-public-offering-of-common</guid> <content:encoded> <![CDATA[ <p align="justify">RAMSEY, N.J. and BOCA RATON, Fla., Oct. 20, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. <br></p> <p align="justify">ADMA intends to use the net proceeds from this offering (i) to advance the commercial sales of its U.S. Food and Drug Administration (FDA)-approved products through the procurement of raw materials for the manufacturing of BIVIGAM® and ASCENIV™; (ii) to expand its plasma collection facility network; (iii) to scale up the manufacturing capacity of its Boca Raton facility and to make continuous improvements in order to adhere to current Good Manufacturing Practice (cGMP) compliance; (iv) to explore business development opportunities; and (v) for general corporate purposes and other capital expenditures.</p> <p align="justify">Raymond James &amp; Associates, Inc. and Cantor Fitzgerald &amp; Co. are acting as joint book-running managers of the proposed offering.</p> <p align="justify">The securities described above are being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-256643) previously filed with the Securities and Exchange Commission (“SEC”) and declared effective by the SEC on August 3, 2021. The preliminary prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Raymond James &amp; Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, or by telephone at (800) 248-8863, or e-mail at prospectus@raymondjames.com, or from Cantor Fitzgerald &amp; Co., Attn: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022 or by email at prospectus@cantor.com.</p> <p align="justify">Before investing in the offering, you should read in their entirety the preliminary prospectus supplement and its accompanying prospectus to be filed with the SEC, and the other documents that the Company has filed with the SEC that will be incorporated by reference in the prospectus supplement and its accompanying prospectus, which will provide more information about the Company and the offering.</p> <p align="justify">This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p> <p align="justify"><strong>About ADMA Biologics, Inc. (ADMA) </strong></p> <p align="justify">ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=hEhEF2Yaw9aWsDwALwT3YjvTK6XXXwR3eGi3rIIGflKYjLoLqldWts7LfsR8qO2wx3EKL7mY1hsYm7_SF3ZAryziAYNbGIq45F9SNnxHLVs=" rel="nofollow" target="_blank">www.admabiologics.com</a>.</p> <p align="justify"><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p> <p align="justify"><em>This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “should,” “could,” “would,” “may,” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include statements about the offering, ADMA’s intention to grant the underwriters a 30-day option to purchase additional shares in the offering, and ADMA’s intended use of proceeds generated from the offering. Actual events or results may differ materially from those described in this document due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering and the risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.</em></p> <p align="justify"><strong>COMPANY CONTACT: </strong></p> <p align="justify">Skyler Bloom<br>Director, Investor Relations and Corporate Strategy | 201-478-5552 | <a href="https://www.globenewswire.com/Tracker?data=3DMxH6rUoQJYk-kJ0ZAz_oVLXszJoOZ4VMWoUZKnvNa2b_ypuey10oXzj02Vb0jAJuRIgDB6PH200WmPkh1amFz1692RD65il0Y7a1HbfV8=" rel="nofollow" target="_blank">sbloom@admabio.com</a> </p> <p align="justify"><strong>INVESTOR RELATIONS CONTACT:</strong><br>Michelle Pappanastos <br>Senior Managing Director, Argot Partners | 212-600-1902 | <a href="https://www.globenewswire.com/Tracker?data=5NIb7rT432UHYDn8Axgw46Xm1pUR5t-PpboQxdiwJk0Sc2UVa4mk4o5ZKinEbhILnHAqcTkmhtecH8abOzgSOvOqRVX5uXYpYbRNEq57wUSV79V9GK7exyh4jap7qrkZ" rel="nofollow" target="_blank">michelle@argotpartners.com</a> </p> <img class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=ODM3Njk5MCM0NDk1NTk1IzIwMjM3MzA="> <br><img src="https://ml.globenewswire.com/media/ZGIwMzBkYmUtNWRlYi00ZTNkLWI5YmYtMWI1NzgxNDRkZjc2LTEwMzUyOTc=/tiny/ADMA-Biologics-Inc-.png"><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/468b61b4-73b9-495e-a4be-f4823782b2fd"><img src="https://ml.globenewswire.com/media/468b61b4-73b9-495e-a4be-f4823782b2fd/small/adma-biologics-rgb-l-092115p-jpg.jpg" border="0" width="150" height="52" alt="Primary Logo"></a></p> Source: ADMA Biologics, Inc. ]]> </content:encoded> </item> <item> <title>ADMA Biologics Announces a Poster Presentation at the 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization Conference</title> <link>https://www.admabiologics.com/investors/press-releases/detail/515/adma-biologics-announces-a-poster-presentation-at-the-2021</link> <pubDate>Tue, 19 Oct 2021 07:00:00 -0400</pubDate> <guid isPermaLink="true">https://www.admabiologics.com/investors/press-releases/detail/515/adma-biologics-announces-a-poster-presentation-at-the-2021</guid> <content:encoded> <![CDATA[ <p align="justify">RAMSEY, N.J. and BOCA RATON, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that a poster presentation will be made at the virtual 2021 International Society for Influenza and other Respiratory Virus Diseases - World Health Organization (ISIRV-WHO) Conference, which will take place on October 19-22. The case documents the use of ASCENIV™, a novel intravenous immune globulin (IGIV) human-slra, as concomitant therapy in a patient presenting with severe respiratory viral disease and COVID-19 infection.<br></p> <p><strong>Abstract Title:</strong><em> Clinical Impact of Concomitant Use of a Novel High-Titer Immune Globulin in an Adult with COVID-19 and Severe Acute Respiratory Distress Syndrome (ARDS)</em></p> <p><strong>Authors:</strong> Gene A. Wetzstein, PharmD, BCOP; Mourad Ismail, MD; Jeffrey Gruenglas, DHSc(c), MBE, MA; Dima A. Decker, PhD; James Mond, MD, PhD</p> <p><strong>Poster Number:</strong> 124</p> <p align="justify"><strong>About ADMA Biologics, Inc. (ADMA)</strong></p> <p align="justify">ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM<sup>®</sup> (immune globulin intravenous, human) for the treatment of PI; and NABI-HB<sup>®</sup> (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=QbmpJ7lv1BVfEJEYdsO6RaT5gzUKXE4b_sgP8fxgqlRejbtFwzG6rwBvFHLT6OHAL-b55jx4mTcyaSuPLZOhjTFSOXgmr9FUQi8Kd5I6nMQ=" rel="nofollow" target="_blank">www.admabiologics.com</a>.</p> <p align="justify"><strong>About ASCENIV™</strong></p> <p align="justify">ASCENIV (immune globulin intravenous, human – slra 10% liquid) is a plasma-derived, polyclonal, intravenous IVIG. ASCENIV was approved by the United States Food and Drug Administration (FDA) in April 2019 and is indicated for the treatment of primary humoral immunodeficiency (PI), also known as primary immune deficiency disease (PIDD), in adults and adolescents (12 to 17 years of age). ASCENIV is manufactured using ADMA’s unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends normal source plasma and respiratory syncytial virus (RSV) plasma obtained from donors tested using the Company’s proprietary microneutralization assay. ASCENIV contains naturally occurring polyclonal antibodies, which are proteins that are used by the body’s immune system to neutralize microbes, such as bacteria and viruses and prevent against infection and disease. ASCENIV is protected by U.S. Patents: 9,107,906, 9,714,283 and 9,815,886. Certain data and other information about ASCENIV can be found by visiting <a href="https://www.globenewswire.com/Tracker?data=2t9C8t205zP-M0BB0Q-OXvIh2CKyaGFEWdvTtfZmdkDvU8Lx9JTbxs77LKSr4tc3SUcTr4E9PAu4_hOeVd52XQ==" rel="nofollow" target="_blank">www.asceniv.com</a>. Information about ADMA and its products can be found on the Company’s website at www.admabiologics.com.</p> <p align="justify"><strong>Additional Important Safety Information about ASCENIV™</strong></p> <p align="justify">ASCENIV™ (immune globulin intravenous, human – slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"> <tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; ">WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE</td></tr> <tr><td style="border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; "> </td></tr> <tr><td style="border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; ">Thrombosis may occur with immune globulin (IGIV) products, including ASCENIV™. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.</td></tr> <tr><td style="border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; "> </td></tr> <tr><td style="border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; ">Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients.</td></tr> <tr><td style="border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; "> </td></tr> <tr><td style="border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; ">Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. ASCENIV™ does not contain sucrose.</td></tr> <tr><td style="border-right: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; "> </td></tr> <tr><td style="border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ; vertical-align: middle; vertical-align: middle ; ">For patients at risk of thrombosis, renal dysfunction or renal failure, administer ASCENIV™ at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.</td></tr> </table> <p align="justify"><br>ASCENIV™ is contraindicated in:</p> <ul type="disc"> <li style="margin-top:13.5pt; margin-bottom:13.5pt; text-align:justify;">Patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin.</li> <li style="margin-top:13.5pt; margin-bottom:13.5pt; text-align:justify;">IgA-deficiency patients with antibodies to IgA and a history of hypersensitivity.</li> </ul> <p align="justify"><strong>Warnings and Precautions</strong></p> <p align="justify">Severe hypersensitivity reactions may occur with IGIV products, including ASCENIV™. In case of hypersensitivity, discontinue ASCENIV™ infusion immediately and institute appropriate treatment. Medications such as epinephrine should be available for treatment of acute hypersensitivity reactions.</p> <p align="justify">Thrombosis may occur following treatment with immunoglobulin products, including ASCENIV™. Thrombosis may occur in the absence of known risk factors.</p> <p align="justify">Acute renal dysfunction/failure, osmotic nephrosis, and death may occur upon use of human IGIV products. Ensure that patients are not volume depleted before administering ASCENIV™. Periodic monitoring of renal function and urine output is particularly important in patients judged to be at increased risk of developing acute renal failure.</p> <p align="justify">Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving IGIV treatment, including ASCENIV™.</p> <p align="justify">Aseptic meningitis syndrome (AMS) may occur with IGIV treatments, including ASCENIV™. AMS may occur more frequently in association with high doses (2 g/kg) and/or rapid infusion of IGIV.</p> <p align="justify">IGIV products, including ASCENIV™, may contain blood group antibodies that can act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin reaction and hemolysis.</p> <p align="justify">Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and the patient’s serum.</p> <p align="justify">Because ASCENIV™ is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.</p> <p align="justify">Periodic monitoring of renal function and urine output is particularly important in patients at increased risk of developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of ASCENIV™ and at appropriate intervals thereafter.</p> <p align="justify">After infusion of immunoglobulin, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs’) test.</p> <p align="justify"><strong>Adverse Reactions</strong></p> <p align="justify">The most common adverse reactions to ASCENIV™ (≥5% of study subjects) were headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea.</p> <p align="justify"><strong>You are encouraged to report side effects of prescription drugs to ADMA Biologics @ 1-800-458-4244 or the FDA. Visit </strong><a href="https://www.globenewswire.com/Tracker?data=tM3zSSPO0LJa0-MwMHlb-1KG2zJfacQ6y2In8JsW481WFiJc5Ubo0CM34Mr_ABuM1TlniZwXV6-uZ6f80NHeDrUq5z_U7eVrPjLKSNm0pMT5WCLYtLOynzgR3pbGIg2fbZCM_tBtlrONcQes4DFEP76N-ahf3SrWfkQQkSnv9NMkBhXJKQI4e2OiF8qMtliz" rel="nofollow" target="_blank">www.fda.gov/MedWatch</a><strong> or call 1-800-FDA-1088.</strong></p> <p align="justify"><strong>COMPANY CONTACT: </strong><br>Skyler Bloom<br>Director, Investor Relations and Corporate Strategy | 201-478-5552 | <a href="https://www.globenewswire.com/Tracker?data=SB8rclw-YG-TUQX7Aa5UTVqg61AIYjjHZrJuF5hQIu2ewATdIxMmqaP3WN_OBBuJ5BZ6Ic1qcYyOJIO72aFxSTg1y987IJdndTzB7iSi-fI=" rel="nofollow" target="_blank">sbloom@admabio.com</a></p> <p align="justify"><strong>INVESTOR RELATIONS CONTACT:</strong><br>Michelle Pappanastos <br>Senior Managing Director, Argot Partners | 212-600-1902 | <a href="https://www.globenewswire.com/Tracker?data=RrFfc8CPKSOhQb-P_JZZrMeiay0nVmzBqQdVbl-YPt1HfOBjNKmvysOofbPOfILOp_QVjCIt5xN0G5F2f3R2lUA-gW7IaXCGzJmaI9mczsgejwlJWDsc-Pzu5Gwgk19N" rel="nofollow" target="_blank">michelle@argotpartners.com</a></p> <img class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=ODM3NTQzNyM0NDkxMDk2IzIwMjM3MzA="> <br><img src="https://ml.globenewswire.com/media/MTgyZmVhYmItMmYwNy00ZTA2LWEwOTAtMTc3MmI5Y2QwZjNmLTEwMzUyOTc=/tiny/ADMA-Biologics-Inc-.png"><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/468b61b4-73b9-495e-a4be-f4823782b2fd"><img src="https://ml.globenewswire.com/media/468b61b4-73b9-495e-a4be-f4823782b2fd/small/adma-biologics-rgb-l-092115p-jpg.jpg" border="0" width="150" height="52" alt="Primary Logo"></a></p> Source: ADMA Biologics, Inc. ]]> </content:encoded> </item> <item> <title>ADMA Biologics Strengthens its Board of Directors with the Appointment of Young T. Kwon, Ph.D.</title> <link>https://www.admabiologics.com/investors/press-releases/detail/514/adma-biologics-strengthens-its-board-of-directors-with-the</link> <pubDate>Mon, 18 Oct 2021 07:00:00 -0400</pubDate> <guid isPermaLink="true">https://www.admabiologics.com/investors/press-releases/detail/514/adma-biologics-strengthens-its-board-of-directors-with-the</guid> <content:encoded> <![CDATA[ <p align="left">RAMSEY, N.J. and BOCA RATON, Fla., Oct. 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the appointment of Young T. Kwon, Ph.D., to its Board of Directors. Dr. Kwon is a highly accomplished corporate executive in the life sciences and biotechnology space. He brings over a decade of expertise in strategic advising, corporate finance and business development transactions to ADMA’s Board.<br></p> <p>“Young is a recognized leader in the healthcare sector and his deep strategic and financial experience will offer invaluable perspectives as ADMA continues to increase revenues for its commercial immunoglobulin (“IG”) product portfolio,” said Steven Elms, Chairman of ADMA’s Board of Directors. “Over the course of his career, Dr. Kwon has held a variety of C-suite leadership positions, in which he played pivotal roles involving multibillion-dollar mergers and acquisitions. We look forward to Young’s expert engagement and assistance in guiding our objectives, including the Company’s evaluation of alternative business opportunities.”</p> <p>“ADMA has established a strong foundation which has enabled the Company to successfully penetrate the rapidly growing U.S. IG market. I am honored to join the Board during this important phase of the Company’s growth and offering advice and guidance on ways to unlock unrealized value from the Company’s vertically integrated biologics manufacturing platform. I very much look forward to leveraging my professional experience to advance ADMA’s strategic and financial goals and ultimately maximizing value for shareholders,” said Dr. Kwon.</p> <p>Dr. Kwon is presently an operating partner at Lightstone Ventures (“LSV”), assisting the LSV biopharmaceutical team with deal sourcing, due diligence, and portfolio management. Prior to LSV, he served as Chief Financial and Business Officer at Momenta Pharmaceuticals, a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, where he most recently led the sale of Momenta to Johnson &amp; Johnson for approximately $6.5 billion in 2020. At Momenta, he led all finance-related and business development initiatives, including those pertaining to the development efforts of M254, Momenta’s hypersialylated IG clinical program. Prior to Momenta, Dr. Kwon was a business development professional at Biogen, driving a variety of transactions.</p> <p>Dr. Kwon received a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University and a B.S. in Biology from MIT.</p> <p align="justify"><strong>About ADMA Biologics, Inc. (ADMA)</strong></p> <p align="justify">ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM<sup>®</sup> (immune globulin intravenous, human) for the treatment of PI; and NABI-HB<sup>®</sup> (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA has received U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and 10,259,865 related to certain aspects of its products and product candidates. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=PkAUTW5xhOvYw6ZwtAFhnpiSwyV7UUPWXTAshy6jNmVGEuT2-2ht_jZD48SKtIQY-7J8EUAZwvYAa2WTw-JJrR3roo0E54VkzyLgFH5R2f4kJfsMgedIO_b3IWCHZ3poIEznBGD9bLuCgFkw4BISTA3_9m2fUJJtp-Y-r3Sj7t8zbHOPOUcpWwQ7CH9AqjILl24fyGFpgR_wJ_TIEdQTycEjDcm4n7PWLnS4tFTzdG9qVbKiRxtxcLQa-ThKHZEm_zRV1IXwZVQxFtAdgGKUqA==" rel="nofollow" target="_blank">www.admabiologics.com</a>.</p> <p align="justify"><strong>COMPANY CONTACT: </strong><br>Skyler Bloom<br>Director, Investor Relations and Corporate Strategy | 201-478-5552 | <a href="https://www.globenewswire.com/Tracker?data=aVrRxBVFm55uJnuVu8Wf5VhU_XbtjPIfnYVL53AHwqxLThzmamvF4sx7Ajzhq1lN_G5kM4CLSFfycSN6hrV0Q5s4aJrNX3vyLENH3Kixb4U=" rel="nofollow" target="_blank">sbloom@admabio.com</a></p> <p align="justify"><strong>INVESTOR RELATIONS CONTACT:</strong><br>Michelle Pappanastos <br>Senior Managing Director, Argot Partners | 212-600-1902 | <a href="https://www.globenewswire.com/Tracker?data=Cnw2g4dGyv_M_YrAIY_hKnwMnkytOkBn2B8HZqYPX9Ic7dg9mmX8LtLQL898AL4qgUBefry9i0auW3LpThzaTvPJUxNyuVZuHzBpz4us557bjFe6XM0W2_QCPs2ysveo" rel="nofollow" target="_blank">michelle@argotpartners.com</a></p> <p> <br></p> <img class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=ODM3NDI5NSM0NDg3NjM4IzIwMjM3MzA="> <br><img src="https://ml.globenewswire.com/media/MzIyZDllNjYtOWIzZi00YWY3LWIzNDMtN2IzYjdiMTVlYWY5LTEwMzUyOTc=/tiny/ADMA-Biologics-Inc-.png"><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/468b61b4-73b9-495e-a4be-f4823782b2fd"><img src="https://ml.globenewswire.com/media/468b61b4-73b9-495e-a4be-f4823782b2fd/small/adma-biologics-rgb-l-092115p-jpg.jpg" border="0" width="150" height="52" alt="Primary Logo"></a></p> Source: ADMA Biologics, Inc. ]]> </content:encoded> </item> </channel> </rss>